



NDA 22404/S-005

SUPPLEMENT APPROVAL

Fortovia Therapeutics, Inc.
Attention: Mary Kay Delmedico, PhD
Vice President, Scientific and Regulatory Affairs
8540 Colonnade Center Drive
Suite 101
Raleigh, NC 27615

Dear Dr. Delmedico:

Please refer to your supplemental new drug application (sNDA) dated June 20, 2019, received June 20, 2019, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ORAVIG (miconazole) buccal tablets, 50 mg.

This Prior Approval supplemental new drug application provides for revisions to the **PRESCRIBING INFORMATION** to comply with the requirements of the Pregnancy and Lactation Labeling Rule (PLLR). Additionally, the **PATIENT INFORMATION** has been reformatted and revised to align with the changes made in the **PRESCRIBING INFORMATION**, and the **INSTRUCTIONS FOR USE** have been revised to make patient information more consistent and concise. Minor editorial revisions have also been made throughout the labeling.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

Joseph Toerner, MD, MPH
Deputy Director for Safety
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOSEPH G TOERNER
02/04/2020 04:14:14 PM